Can-Fite liver drug succeeds in Phase I trial

The drug was found to be safe at all the dosages tested.

Drug development company Can-Fite BioPharma Ltd. (TASE:CFBI) today announced that its CF102 drug for the treatment of liver cancer, hepatitis C and other liver diseases succeeded in Phase I clinical trials. The trials were conducted under an IND application with the US Food and Drug Administration (FDA).

The trial aimed at finding the CF102's safety profile, level in the blood, and dosage range for advanced human clinical trials. The targets were achieved in full and the drug was found to be safe at all the dosages tested.

CF102, which was developed on the basis of Can-Fite's technology platform, is a targeted drug that binds with high affinity to the A3 adenosine receptor. This receptor is highly expressed on the surface of cancer cells but not on normal cells. CF102 binds to its target on cancer cells and triggers programmed cell death (apoptosis).

CF102 is Can-Fite's second drug under development. CF101 for rheumatoid arthritis is undergoing Phase IIb clinical trials.

Published by Globes [online], Israel business news - - on May 4, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018